← Eichor
Study identifier: NCT07227792 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer

Condition: Head and Neck Carcinoma  ·  Sponsor: Yvonne Mowery

PhaseNA
Planned participants35
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Our institution recently began incorporating a novel "tongue-out" radiation therapy (TORT) technique for patients with head and neck tumors at particular subsites (oropharynx, larynx, hypopharynx). Protruding the tongue, i.e. "tongue-out" position, induces anatomical changes that facilitate decreased radiation dose to the oral tongue and PCM. The long-term goal is to determine whether TORT results in reduced severity and faster recovery from acute treatment-related toxicities (particularly mucositis, dysphagia, and dysgeusia) and improved long-term swallowing function and taste compared to traditional "tongue-in" RT for patients with HNC.

This description comes directly from the study's public registry record.

Talk to the study team

Samantha Demko, RN  ·  412-623-1400  ·  albesl@upmc.edu

Brieanna Marino, MS  ·  4126478258  ·  rowlesbm@upmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UPMC Hillman Cancer CenterPittsburgh, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07227792